GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

Goldman Sachs says the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices published its final agenda ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizer’s RSV vaccine, Abrysvo, which GSK claimed infringed on its own RSV shot, Arexvy.

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's ...

GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory ...

vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. GSK and Pfizer said in the filing, opens new tab that they ...

This committee recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...